Simple Summary HER2 intratumoral heterogeneity (ITH) is a well-known phenomenon in
breast cancer, defined as the coexistence of subpopulations of tumor cells with different …

N-acetylcysteine (NAC) is a widely used antioxidant with therapeutic potential. However, the
cancer-promoting effect of NAC observed in some preclinical studies has raised concerns …

Breast cancer is one of the major causes of mortality in women worldwide. The most
aggressive breast cancer subtypes are human epidermal growth factor receptor-positive …

Nucleic acid aptamers are short RNA-or DNA-based affinity reagents typically selected from
combinatorial libraries to bind to a specific target such as a protein, a small molecule, whole …

Breast cancer patients with high levels of human epidermal growth factor receptor 2 (HER2)
expression have worse clinical outcomes. Anti‐HER2 monoclonal antibody (mAb) is the …

Cancer treatments that use a combination of approaches with the ability to affect multiple
disease pathways have proven highly effective. The present study reports on CXCR4 …

Overexpression of human epidermal growth factor receptor 2 (HER2) plays important roles
in tumorigenesis and tumor progression in breast cancer. Nuclear imaging of HER2 …

Background Women may have incomplete understanding of a breast cancer diagnosis,
leading to inaccurate reporting in epidemiological studies. However, it is not feasible to …

Molecular targets serve a crucial role in drug development. Herein, we discovered a novel
peptide that can specifically target the human epidermal growth factor receptor 2 (HER2) …

Introduction Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity.
In this randomized, double-blind, placebo-controlled phase III trial, we assessed first-or …